- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03109223
Addition to Infant Formula of 2-fucosyllactose (2-FL) (2-FL)
Effects of Addition to Infant Formula of 2-fucosyllactose (2-FL) on Growth, Fecal Bacterial Populations and Safety
OBJECTIVES:
Primary:
The primary objective is to determine whether the mean weight gain over a 16-week interval starting on or before 14 days of life differs between infants fed one of two infant formulas as their sole source of nutrition: a commercial formula using a canola l fat blend (Control, E23) or the same formula containing the human milk oligosaccharide (Test (HMO) 2-fucosyllactose (2FL). Mean weight gain also will be compared to that of a concurrently enrolled reference group of exclusively breastfed infants.
Study Overview
Detailed Description
METHODOLOGY/ STUDY DESIGN: This study is double blinded-randomized controlled trial with two arms and a reference breast fed group. The experimental variable is the composition of infant formula fed to healthy term infants for a period of 16 weeks upon entering the study as their sole source of nutrition. The formulations are a commercial control (Control, NPS-E23); and the control formula containing the human milk oligosaccharide (HMO) 2-fucosyllactose (2FL) at 1g/L (HMO, NPS-E23XA).
Infants will be enrolled on or before 14 days of age and fed a study assigned formula for 16 weeks. Weight, length and head circumference will be measured at baseline and 2, 4, 6, 8, 12 and 16 weeks of study entry. Formula volume will be recorded for a three-day period before each visit. Fecal samples will be obtained at baseline (convenience samples) and at week 16 for all subjects and analyzed for microbial populations. Buccal cheek cells of all infants, and mothers of breast fed infants, obtained by swab at week 16 will be genotyped for FUT2. Information on adverse events and new/change of medications will be collected at in person visits and by telephone interviews between in-person visits.
NUMBER OF SUBJECTS: It is estimated that approximately up to approximately 200 subjects will be enrolled in the formula groups to obtain up to approximately 65 evaluable per protocol subjects in each group. As non-randomized reference group of approximately 85 breastfed infants will be enrolled to obtain approximately 65 evaluable infants.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
San Pedro Sula, Honduras
- Hospital Clinica Bendana
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Alabama Clinical Therapeutics, LLC
-
-
Indiana
-
Evansville, Indiana, United States, 47715
- Qualmedica Research, LLC dba Pedia Research, LLC
-
-
New York
-
Bronx, New York, United States, 10468
- Advantage Clinical Trials
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- JBR Clinical Research
-
-
Virginia
-
Burke, Virginia, United States, 22015
- PI-Coor Clinical Research, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. At birth:
- Healthy, term (37-42 weeks), appropriate for gestational age 2. At the time of enrollment:
- < 14 days post-natal age at time of enrollment, either gender
- Exclusively formula fed or breastfed upon enrollment Subject must be in general good health and free from any clinically significant disease, condition, or illness that might interfere with the study evaluations. Prior labs must be present to confirm good health.
- Formula group infants: Mother has determined to use infant formula exclusively for feeding her baby through at least 16 weeks.
- Reference breastfed infants: Mother has determined to breastfeed exclusively through at least 16 weeks Written informed consent of parent/guardian, prior to any study related procedures being performed.
Exclusion Criteria:
1. Any clinically significant abnormal findings, as determined by the investigator, on the subject's medical history or physical exam during screening.
2. Use of systemic medications by the subject that in the Investigator's opinion could impact evaluation of the subject's assessments.
3. Discontinuation of exclusive breastfeeding by reference group (breastfed) infants.
4. Fed with baby/solid foods on average more than once per day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Commercially availabel infant formula
|
Infant formula
|
EXPERIMENTAL: Test formula with 2-FL
|
Infant formula
|
ACTIVE_COMPARATOR: Breast Fed
|
Infant formula
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Growth
Time Frame: 4 months
|
Growth as compared to WHO Growth Charts
|
4 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PRG-VA-17-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth of Infants
-
Mead Johnson NutritionCompletedGrowth of Term InfantsUnited States
-
Mead Johnson NutritionCompletedGrowth of Term InfantsUnited States
-
Mead Johnson NutritionCompleted
-
Universidad Autónoma de QuerétaroNUCITEC S.A. de C.V.CompletedGrowth & Development | Formula Feeding of Healthy Full Term Infants | Breast Feeding of Healthy Full Term InfantsMexico
-
Perrigo NutritionalsCompletedGrowth | Healthy Term InfantsUnited States
-
The University of Texas Health Science Center,...UnknownMalnutrition | Growth Failure | Nutrition | Nutrition Disorder, Infant | Growth Failure in Medically Complex Infants | Malnutrition in Medically Complex Infants | Nutrition in Medically Complex InfantsUnited States
-
Assiut UniversityUnknownInfants Aged One Month to 2 Years , Infants With Any Type of Feeding (Breast or Artificial or Weaned Attend Assiut University Children Hospital )
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedPostnatal Growth Failure of Preterm Infants | Human Milk Fortification
-
Heinz Italia SpAUniversity of Cagliari; IRCCS Policlinico S. MatteoCompletedFormula Feeding of Healthy Full Term Infants | Breast Feeding of Healthy Full Term InfantsItaly
Clinical Trials on sole source nutrition
-
Meir Medical CenterUnknown
-
University of FloridaScientific Motion Technologies, Inc.Withdrawn
-
The Hong Kong Polytechnic UniversityTung Wah College; MindvividNot yet recruitingFrailty | Body Composition | Cognitive Function | Nutrition | Cognitive Frailty | Protective Diet Adherence
-
Istanbul Kent UniversityBezmialem Vakif UniversityCompletedDiabetic Foot | Diabetic NeuropathiesTurkey
-
University Hospital, BrestCompleted
-
Wilfrid Laurier UniversityUnknown
-
Universidad Complutense de MadridCompletedDiabetic Foot | Diabetic Foot UlcerSpain
-
National Taiwan University HospitalUnknownExposure to Infrared RadiationTaiwan
-
Universitätsklinikum Hamburg-EppendorfEuropean UnionCompletedDepression | Sleep | Well-being | Cognitive Function | Ultrasound | Brain FunctionGermany
-
University Children's Hospital BaselSwiss Federal Institute of Technology; Bern University of Applied SciencesCompletedCerebral Palsy | Leg Length InequalitySwitzerland